RNAi Quantification via ProxiQuant™ Technology
Understanding the efficacy of RNA interference (RNAi) necessitates development
of a comprehensive dose-response correlation within target cells and body fluids.
International Therapeutics has developed an accurate non-radioactive method, ProxiQuant™,
to measure RNAi in biological samples.
ProxiQuant™ is a novel enzymatic application enabling stoichiometric generation
of surrogate DNA targets from primary RNAi molecules in biological samples. Whereas
RT-PCR enzymology utilizes Reverse Transcriptases to generate DNA from RNA, ProxiQuant™
takes advantage of Ligases to create larger DNA molecules from smaller RNAi. These
resulting “Proxy-Target” DNA molecules can be quantified using preferred
instruments and methods such as Real-Time PCR or Branched-DNA technology. ProxiQuant™
has been utilized to quantify RNAi dose with a sensitivity of one zeptomole (10-21
ITI is seeking to out-license the ProxiQuant™ technology for research, analysis
of clinical samples, or commercialization as a kit.